UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

The Lancet (British edition), 2017-02, Vol.389 (10068), p.519-527

2017

Volltextzugriff (PDF)

Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma

Cancer cell, 2013-09, Vol.24 (3), p.275-277

Orlowski, Robert Z.

2013

Volltextzugriff (PDF)

Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma

Cell metabolism, 2021-01, Vol.33 (1), p.78-93.e7

2021

Volltextzugriff (PDF)

A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer

Cancer cell, 2013-12, Vol.24 (6), p.791-805

2013

Volltextzugriff (PDF)

The Immunoproteasome as a Target in Hematologic Malignancies

Seminars in hematology, 2012-07, Vol.49 (3), p.258-262

2012

Volltextzugriff (PDF)

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups

Clinical lymphoma, myeloma and leukemia, 2019-08, Vol.19 (8), p.522-530.e1

2019

Volltextzugriff (PDF)

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

The lancet oncology, 2017-10, Vol.18 (10), p.1327-1337

2017

Volltextzugriff (PDF)

Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models

Leukemia research, 2015-03, Vol.39 (3), p.371-379

2015

Volltextzugriff (PDF)

Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials

Seminars in oncology, 2013-10, Vol.40 (5), p.634-651

Orlowski, Robert Z

2013

Volltextzugriff (PDF)

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

The lancet oncology, 2016-01, Vol.17 (1), p.27-38

2016

Volltextzugriff (PDF)

Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2017-07, Vol.17 (7), p.424-432

2017

Volltextzugriff (PDF)

NF-κB as a therapeutic target in cancer

Trends in Molecular Medicine, 2002-08, Vol.8 (8), p.385-389

2002

Volltextzugriff (PDF)

Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy

International journal of radiation oncology, biology, physics, 2024-05, Vol.119 (1), p.193-199

2024

Volltextzugriff (PDF)

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2012-10, Vol.12 (5), p.310-318

2012

Volltextzugriff (PDF)

The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration

The international journal of biochemistry & cell biology, 2012-07, Vol.44 (7), p.1166-1173

2012

Volltextzugriff (PDF)

Biological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2013-09, Vol.13 (2), p.S317-S329

2013

Volltextzugriff (PDF)

Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation

Biology of blood and marrow transplantation, 2018-11, Vol.24 (11), p.2197-2203

2018

Volltextzugriff (PDF)

Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway

Cancer epidemiology, 2021-08, Vol.73, p.101972-101972, Article 101972

2021

Volltextzugriff (PDF)

Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study

Clinical lymphoma, myeloma and leukemia, 2020-05, Vol.20 (5), p.e221-e238

2020

Volltextzugriff (PDF)

Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia

Clinical lymphoma, myeloma and leukemia, 2019-09, Vol.19 (9), p.560-569

2019

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(81)

Sprache

Englisch
(81)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(41)
Science & Technology
(41)
Humans
(34)
Oncology
(28)
Hematology, Oncology And Palliative Medicine
(27)
Hematology
(24)
Female
(21)
Multiple Myeloma
(20)
Male
(19)
Aged
(18)
Middle Aged
(17)
Multiple Myeloma - Drug Therapy
(15)
Treatment Outcome
(14)
Adult
(13)
Bortezomib
(10)
Multiple Myeloma - Pathology
(10)
Animals
(9)
Transplantation
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Cell Biology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma

Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma

A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

The Immunoproteasome as a Target in Hematologic Malignancies

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma

NF-κB as a therapeutic target in cancer

Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy

Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration

Biological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma

Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation

Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway

Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study

Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia

Aktive Filter

Suchergebnisse filtern